Best Practices in Expanding Access to Bispecific Antibodies and ...

To optimize care for patients being treated with bispecific antibodies and to explore early identification and management of adverse events common in ...

BISPECIFIC ANTIBODIES AND ADVERSE EVENT MANAGEMENT

In 2022, ACCC launched a new project which builds upon its previous work titled, “Best Practices in Expanding Access to Bispe- cific Antibodies and Adverse ...

Expanding Access to Cellular and Bispecific Therapies - SITC

Education across the entire care continuum serves as the foundation for any cellular therapy and/or bispecific program. Developing strategies for engaging ...

Best practices in expanding access to bispecific antibodies...

Today's resource explores how to expand patient access to #bispecific #antibodies and optimize the early identification and management of...

Use of bispecific antibodies (BsAbs) in community practices

Results: Catalysts for developing CRS workflows were the addition of BsAbs to the practice formulary, identification of practice leaders willing ...

Design and Production of Bispecific Antibodies - PMC

... Good Manufacturing Practice (GMP) conditions [27]. ... accessed on 4 July 2019 ... Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.

Best Practices For Uptake and Use of Bispecific Therapy

The impact of bispecific agents on patients, particularly in terms of pharmacokinetics, dynamics, and the onset of CRS (cytokine release ...

Operationalizing Bispecific Antibodies Across Academic and ...

Proactive acceleration of prior authorization of both BsAbs and supportive care infusions associated with treatment is essential in preventing ...

Current landscape and future directions of bispecific antibodies in ...

Bispecific antibody-based tumor immunotherapy has gained broad potential in preclinical and clinical investigations in a variety of tumor types following ...

Bispecific Therapies in Community Oncology: Bridging Insights from ...

Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand ...

Can we make better CAR-Ts and bispecific antibodies?

Novel manufacturing techniques hold the potential to reduce side effects, while quicker and more cost-effective methods may expand access to ...

Approaches to Increase Equitable Access to and Delivery of Quality ...

Additionally, the introduction of these novel bispecific antibodies creates a need to standardize coordination of care and share best practices ...

Bispecific antibodies: advancing precision oncology: Trends in Cancer

Thus far, a total of seven bsAbs have received regulatory approval for use in hematological malignancies and four in select solid tumors, with ...

Community Cancer Programs Lead the Way in Expanding Bispecific ...

Effective implementation involves interprofessional communication, patient safety education, and financial planning to ensure optimal care ...

Multiple Myeloma Resource Center - JADPRO Clinical Case Series

This includes CAR-T, a one-time cellular therapy with important pre- and post-treatment considerations, and bispecific antibodies (BsAb), which ...

Bispecific antibodies in the treatment of multiple myeloma - Nature

Daratumumab has been shown to deplete CD38+ Tregs and promote activation and clonal expansion of cytotoxic T-cells [79]. IMiDs, including ...

Optimizing Bispecific Antibody Therapy in Multiple Myeloma

... access to care, evidence-based cancer treatment ... The expanding therapeutic options and increasing ... Best Practices for Optimizing Teclistamab Therapy.

The How and Why of Bispecific Antibodies for R/R DLBCL - CCO

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care · Clinical Education Alliance Terms and Conditions · Clinical Education ...

Protocol For Urgent and Around-the-Clock Bispecific Care

She notes that such coordination can expand patient access and clinical trial enrollment. The discussion centers on how strong partnerships ...

The Role of Bispecific Antibodies in Managing Diffuse Large B-Cell ...

This dynamic course focuses on the exchange of best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility.